Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TRVI 
Trevi Therapeutics Inc (TRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TRVI (5-star) is a STRONG-BUY. BUY since 38 days. Profits (41.08%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 51.94% | Avg. Invested days 33 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 581.06M USD | Price to earnings Ratio - | 1Y Target Price 19.83 |
Price to earnings Ratio - | 1Y Target Price 19.83 | ||
Volume (30-day avg) 3488738 | Beta 0.91 | 52 Weeks Range 2.30 - 7.39 | Updated Date 04/1/2025 |
52 Weeks Range 2.30 - 7.39 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.47 |
Earnings Date
Report Date 2025-03-18 | When Before Market | Estimate -0.1171 | Actual -0.11 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.15% | Return on Equity (TTM) -52.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 500574398 | Price to Sales(TTM) - |
Enterprise Value 500574398 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.92 | Shares Outstanding 96682200 | Shares Floating 73666058 |
Shares Outstanding 96682200 | Shares Floating 73666058 | ||
Percent Insiders 0.9 | Percent Institutions 86.28 |
Analyst Ratings
Rating 4.67 | Target Price 9.94 | Buy 3 | Strong Buy 6 |
Buy 3 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Trevi Therapeutics Inc
Company Overview
History and Background
Trevi Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic pruritus (itching) and other chronic conditions. Founded to address unmet medical needs, it has focused primarily on Haduviou2122 (nalbuphine ER) for pruritus associated with various conditions. Further background on exact founding year not available.
Core Business Areas
- Pruritus Therapeutics: Development and commercialization of Haduviou2122 (nalbuphine ER) for chronic pruritus associated with prurigo nodularis.
Leadership and Structure
Trevi Therapeutics has a management team led by its CEO and a board of directors providing oversight. Specific individuals' names and organizational chart unavailable without live data.
Top Products and Market Share
Key Offerings
- Haduviou2122 (nalbuphine ER): Haduviou2122 is an extended-release oral formulation of nalbuphine being developed for the treatment of chronic pruritus associated with prurigo nodularis. Market share data is not publicly available. Key competitors in the pruritus market include companies developing and marketing topical corticosteroids, antihistamines, calcineurin inhibitors, and other novel therapies. Specific competitor names with drugs for prurigo nodularis include Sanofi's Dupixent (dupilumab).
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and research-intensive, marked by lengthy development timelines, regulatory hurdles, and high risk of failure. There's increasing demand for therapies addressing unmet needs in chronic conditions.
Positioning
Trevi Therapeutics is positioned as a company specializing in chronic pruritus, particularly prurigo nodularis, leveraging its Haduviou2122 product candidate. Its competitive advantage lies in targeting a specific patient population with a novel therapy.
Total Addressable Market (TAM)
The total addressable market for pruritus therapies is significant and growing, driven by the prevalence of chronic skin conditions. Trevi Therapeutics is positioned to capture a portion of this market by focusing on severe chronic itch associated with prurigo nodularis. Specific TAM not available.
Upturn SWOT Analysis
Strengths
- Novel therapy targeting unmet medical need
- Potential for first-in-class treatment
- Experienced management team
Weaknesses
- Single product reliance
- High development costs
- Regulatory risks
- Commercialization challenges
Opportunities
- Expansion to other pruritus indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Increasing awareness of prurigo nodularis
Threats
- Competition from established therapies
- Failure to obtain regulatory approval
- Unfavorable reimbursement environment
- Patent expiration
Competitors and Market Share
Key Competitors
- Sanofi (SNY)
- Regeneron (REGN)
- Galderma (Not Publicly Traded)
- Kyowa Kirin (KYKOF)
Competitive Landscape
Trevi faces competition from companies with established pruritus therapies and larger market presence. Its success depends on demonstrating the efficacy and safety of Haduviou2122.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends depend on past financial performance. Requires real-time financial data.
Future Projections: Future projections depend on analyst estimates, clinical trial outcomes, and regulatory approvals. Unavailable without real-time analyst reports.
Recent Initiatives: Recent initiatives include advancing the clinical development program for Haduviou2122.
Summary
Trevi Therapeutics is a biopharmaceutical company focused on developing Haduviou2122 for chronic pruritus. The company addresses a significant unmet medical need. However, it faces challenges related to single product reliance, competition, and regulatory hurdles. Successful clinical trials and commercialization are essential for its future growth.
Similar Companies
ITCI
Intracellular Th
ITCI
Intracellular Th
KALV
Kalvista Pharmaceuticals Inc
KALV
Kalvista Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Market share percentages are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevi Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2019-05-07 | Co-Founder, CEO, President & Director Ms. Jennifer L. Good | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | |
Full time employees 26 | |||
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is based in New Haven, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.